Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

CLL-487 First-Line Fixed-Duration Ibrutinib Plus Venetoclax (ibr+ven) Vs Chlorambucil Plus Obinutuzumab (clb+o): 55-Month Follow-Up from the GLOW Study

Carol Moreno,Talha Munir,Carolyn Owen,George Follows,José-Ángel Hernández-Rivas,Ohad Benjamini,Ann Janssens,Mark-David Levin,Tadeusz Robak,Martin Simkovic,Sergey Voloshin,Vladimir Vorobyev,Munci Yagci,Loic Ysebaert,Qianya Qi, Emma Smith,Srimathi Srinivasan,Natasha Schuier,Kurt Baeten,Donne Bennett Caces

Clinical Lymphoma Myeloma and Leukemia（2024）

Cited 0|Views3
Key words
CLL,chronic lymphocytic leukemia,ibrutinib,venetoclax,fixed-duration regimen,minimal residual disease (MRD),trial-in-progress
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined